Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
Michael G. Silverman(Harvard University), Marc S. Sabatine(Brigham and Women's Hospital)
Cited by 1,459
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k